Lower US sales of generic Revlimid dragged down second-quarter earnings, but double-digit growth in base markets and the upcoming relaunch of semaglutide offer near-term relief.
More in Finance
IIT Bombay scholar builds low cost air purifier starting at ₹2,000, can bring down AQI by 85% – How he did it? Details
October 23, 2026
Adani Power profit surges on high power demand, tariffs, beats street estimates
October 23, 2026
Meet Sukhbir Singh Sandhu, Vivek Joshi – No action by govt despite ECs flagging conduct of an ECI official, RTI shows
October 23, 2026
Indian-origin lab owner charged in $66 million COVID-19 test fraud: How the alleged US healthcare scam worked
October 23, 2026
Tata Motors returns to profit with ₹1,254 crore in Q2 earnings as CV sales rise 42%
October 23, 2026
From layoff to ₹1.5 crore UAE offer: How reskilling helped a tech professional rebuild his career and boost earnings
October 23, 2026
Latest News
Green councillors face Labour deadline to disown Zionism policy
October 23, 2026
Trump says Burnham is 'getting it done' after Jackdaw decision
October 23, 2026
Ex-Tory campaign chief and his wife receive suspended sentences over election bets
October 23, 2026
Trump Blasts Vanity Fair Over ‘Fake News’ On Jared Kushner’s Alleged Undisclosed Foreign Bank Accounts
October 23, 2026
Police yet to receive £2m after A66 crash, says commissioner
October 23, 2026
Republicans’ Chances Of Maintaining House Majority Have ‘All But Evaporated’ Cook Political Report Says
October 23, 2026